Helmut Niederhofer1, Kai von Klitzing. 1. Child and Adolescent Psychiatry, Saechsisches Krankenhaus Rodewisch, Rodewisch, Germany. helmutniederhofer@yahoo.de
Abstract
BACKGROUND:Bright light therapy, an effective therapeutic option for depressive adults, could provide safe, economic, and effective rapid recovery also in adolescents. METHODS:Twenty-eight volunteers, between 14 and 17 years old and suffering from mild depressive disorder according to DSM-IV criteria, completed the study. This was a randomized cross-over trial, i.e. that 14 patients received firstplacebo (50 lux) for 1 h a day for 1 week and then bright light therapy (2,500 Lux) for 1 week. Fourteen patients receivedfirst bright light therapy and then placebo. For assessment of depressive symptoms, Beck's depression inventory scales were administered 1 week before and 1 day before placebo treatment, on the day between placebo and verum treatment, on the day after verum treatment and 1 week after verum treatment. Saliva melatonin and cortisol samples were collected at 08:00 and 20:00 h, 1 week before and 1 day before placebo treatment, on the day between placebo and verum treatment, on the day after verum treatment and 1 week after verum treatment and assayed for melatonin and cortisol to observe any change in circadian timing. RESULTS:BDI scores improved significantly. The assays of saliva showed significant differences between treatment and placebo. No significant adverse reactions were observed. CONCLUSION:Antidepressant response to bright light treatment in this age group was statistically superior to placebo.
RCT Entities:
BACKGROUND: Bright light therapy, an effective therapeutic option for depressive adults, could provide safe, economic, and effective rapid recovery also in adolescents. METHODS: Twenty-eight volunteers, between 14 and 17 years old and suffering from mild depressive disorder according to DSM-IV criteria, completed the study. This was a randomized cross-over trial, i.e. that 14 patients received first placebo (50 lux) for 1 h a day for 1 week and then bright light therapy (2,500 Lux) for 1 week. Fourteen patients received first bright light therapy and then placebo. For assessment of depressive symptoms, Beck's depression inventory scales were administered 1 week before and 1 day before placebo treatment, on the day between placebo and verum treatment, on the day after verum treatment and 1 week after verum treatment. Saliva melatonin and cortisol samples were collected at 08:00 and 20:00 h, 1 week before and 1 day before placebo treatment, on the day between placebo and verum treatment, on the day after verum treatment and 1 week after verum treatment and assayed for melatonin and cortisol to observe any change in circadian timing. RESULTS: BDI scores improved significantly. The assays of saliva showed significant differences between treatment and placebo. No significant adverse reactions were observed. CONCLUSION: Antidepressant response to bright light treatment in this age group was statistically superior to placebo.
Authors: Hira Mohyuddin; Polymnia Georgiou; Abhishek Wadhawan; Melanie L Daue; Lisa A Brenner; Claudia Gragnoli; Erika F H Saunders; Dietmar Fuchs; Christopher A Lowry; Teodor T Postolache Journal: Pteridines Date: 2017-12-02 Impact factor: 0.581
Authors: Ryan W Logan; Brant P Hasler; Erika E Forbes; Peter L Franzen; Mary M Torregrossa; Yanhua H Huang; Daniel J Buysse; Duncan B Clark; Colleen A McClung Journal: Biol Psychiatry Date: 2017-12-15 Impact factor: 13.382
Authors: Justin K Siemann; Piper Williams; Turnee N Malik; Chad R Jackson; Noah H Green; Ronald B Emeson; Pat Levitt; Douglas G McMahon Journal: Sci Rep Date: 2020-09-22 Impact factor: 4.379